Kolkata News Today

Myelodysplastic Syndrome Pipeline Insight | Companies – Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, AbbVie, BeiGene, and Others

 Breaking News
  • No posts were found

Myelodysplastic Syndrome Pipeline Insight | Companies – Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, AbbVie, BeiGene, and Others

May 24
15:50 2023
Myelodysplastic Syndrome Pipeline Insight | Companies - Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, AbbVie, BeiGene, and Others

DelveInsight’s, “Myelodysplastic Syndrome Pipeline Insight 2023” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in the Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including Myelodysplastic Syndrome clinical trials and nonclinical stage products. It also covers the Myelodysplastic Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Myelodysplastic Syndrome Pipeline treatment landscape of the report, click here @ Myelodysplastic Syndrome Pipeline Outlook

 

Key Takeaways from the Myelodysplastic Syndrome Pipeline Report

  • DelveInsight’s Myelodysplastic Syndrome Pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Myelodysplastic Syndrome.
  • The leading Myelodysplastic Syndrome Companies include Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others
  • Promising Myelodysplastic Syndrome Pipeline Therapies include Luspatercept, Lenalidomide 5 mg, Tamibarotene + Azacitidine, Group 1: Epoetin alfa, Lemzoparlimab+Azacitidine, and others
  • The Myelodysplastic Syndrome companies and academics are working to assess challenges and seek opportunities that could influence Myelodysplastic Syndrome R&D. The Myelodysplastic Syndrome therapies under development are focused on novel approaches to treat/improve Myelodysplastic Syndrome.

 

For further information, refer to the detailed Myelodysplastic Syndrome Unmet Needs, Myelodysplastic Syndrome Market Drivers, and Myelodysplastic Syndrome Market Barriers, click here for Myelodysplastic Syndrome Ongoing Clinical Trial Analysis

 

Myelodysplastic Syndrome Overview

Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. Some patients with MDS may have a transformation into acute myeloid leukemia (AML). MDS is usually diagnosed in older patients over the age of 65. Clinical manifestations include a decrease in the number of red blood cells (RBC), platelets, and white blood cells (WBC). The disease course is variable.

 

Request a sample and discover the recent advances in Myelodysplastic Syndrome Ongoing Clinical Trial Analysis and Medications, click here @ Myelodysplastic Syndrome Treatment Landscape

 

Myelodysplastic Syndrome Emerging Drugs

 

  • MBG453: Novartis

Sabatolimab (MBG453) is a humanized monoclonal antibody (hIgG4, S228P) directed against the human T-cell immunoglobulin domain and mucin domain-3 (TIM-3). TIM-3 is a novel target expressed on multiple immune cell types and leukemic cells and blasts but not on the normal stem cells that induce blood formation. Currently, the drug is in the Phase III stage of its development for the treatment of Myelodysplastic syndromes.

  • Tamibarotene: Syros Pharmaceuticals

Tamibarotene (formerly SY-1425) is an oral selective retinoic acid receptor alpha (RARa) agonist. The company is developing treatments for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene. Approximately 50% of MDS patients and 30% of AML patients have RARA overexpression. When RARa is expressed in excess of its tightly controlled natural ligand, cells in the bone marrow may not differentiate into healthy myeloid cells, which can lead to hematological malignancies. However, when oral tamibarotene is administered, tamibarotene binds to RARa, allowing for the restoration of gene expression and myeloid differentiation. The company is currently investigating tamibarotene in the Phase III SELECT-MDS-1 trial in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA overexpression.

  • CA-4948: Curis

CA-4948, which is being developed by Curis, is a small-molecule IRAK4 kinase inhibitor. Inhibition of IRAK4-L activity with emavusertib (CA-4948) blocks leukemic growth in non-clinical experiments. Because IRAK4 plays a central role in this pathway, it is considered an attractive target for the generation of therapeutics to treat these B-cell malignancies as well as certain inflammatory diseases. As part of the collaboration with Aurigene, in October 2015, Curis exclusively licensed a program of orally available, small molecule inhibitors of IRAK4 kinase, including emavusertib (CA-4948). Currently, the drug is in the Phase II stage of its development for the treatment of Myelodysplastic syndromes.

  • RVU120: Ryvu Therapeutics

RVU120 (SEL120) is a specific, selective inhibitor of CDK8 and its paralog, CDK19. A first-in-human Phase Ib clinical trial with RVU120 in patients with AML or high-risk (HR)-MDS is currently ongoing. Preclinical studies indicated the strong antileukemic potential of RVU120, which was often associated with the multilineage commitment of CD34+ AML cells. Moreover, RVU120 could improve proliferation and induce erythroid differentiation of CD34+ cells derived from Diamond-Blackfan anemia (DBA) patients.

 

Dive deep into rich insights for drugs for Myelodysplastic Syndrome Market Drivers and Myelodysplastic Syndrome Market Barriers, click here @ Myelodysplastic Syndrome Unmet Needs and Analyst Views

 

Myelodysplastic Syndrome Pipeline Therapeutics Assessment

There are approx. 120+ key companies which are developing the therapies for Myelodysplastic Syndrome. The companies which have their Myelodysplastic Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Novartis.

 

Scope of the Myelodysplastic Syndrome Pipeline Report

  • Coverage- Global
  • Myelodysplastic Syndrome Companies- Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others
  • Myelodysplastic Syndrome Pipeline Therapies- Luspatercept, Lenalidomide 5 mg, Tamibarotene + Azacitidine, Group 1: Epoetin alfa, Lemzoparlimab+Azacitidine, and others.
  • Myelodysplastic Syndrome Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Myelodysplastic Syndrome Mergers and acquisitions, Myelodysplastic Syndrome Licensing Activities @ Myelodysplastic Syndrome Emerging Drugs, and Recent Trends

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Myelodysplastic Syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Myelodysplastic Syndrome– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. MBG453: Novartis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CA-4948: Curis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. RVU120: Ryvu Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Myelodysplastic Syndrome Key Companies
  21. Myelodysplastic Syndrome Key Products
  22. Myelodysplastic Syndrome- Unmet Needs
  23. Myelodysplastic Syndrome- Market Drivers and Barriers
  24. Myelodysplastic Syndrome- Future Perspectives and Conclusion
  25. Myelodysplastic Syndrome Analyst Views
  26. Myelodysplastic Syndrome Key Companies
  27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services